As of 2025-01-16, the EV/EBITDA ratio of Cara Therapeutics Inc (CARA) is 0.20. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CARA's latest enterprise value is -16.67 mil USD. CARA's TTM EBITDA according to its financial statements is -84.83 mil USD. Dividing these 2 quantities gives us the above CARA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.3x - 10.0x | 8.4x |
| Forward P/E multiples | 12.8x - 18.6x | 16.2x |
| Fair Price | (230.18) - (177.10) | (220.16) |
| Upside | -5261.0% - -4070.9% | -5036.3% |
| Date | EV/EBITDA |
| 2025-01-07 | 0.17 |
| 2025-01-06 | 0.15 |
| 2025-01-03 | 0.16 |
| 2025-01-02 | 0.15 |
| 2024-12-31 | 0.11 |
| 2024-12-30 | 0.21 |
| 2024-12-27 | 0.19 |
| 2024-12-26 | 0.15 |
| 2024-12-24 | 0.14 |
| 2024-12-23 | 0.14 |
| 2024-12-20 | 0.16 |
| 2024-12-19 | 0.17 |
| 2024-12-18 | 0.27 |
| 2024-12-17 | 0.28 |
| 2024-12-16 | 0.27 |
| 2024-12-13 | 0.27 |
| 2024-12-12 | 0.27 |
| 2024-12-11 | 0.26 |
| 2024-12-10 | 0.26 |
| 2024-12-09 | 0.25 |
| 2024-12-06 | 0.26 |
| 2024-12-05 | 0.26 |
| 2024-12-04 | 0.26 |
| 2024-12-03 | 0.26 |
| 2024-12-02 | 0.25 |
| 2024-11-29 | 0.24 |
| 2024-11-27 | 0.25 |
| 2024-11-26 | 0.25 |
| 2024-11-25 | 0.24 |
| 2024-11-22 | 0.24 |
| 2024-11-21 | 0.24 |
| 2024-11-20 | 0.24 |
| 2024-11-19 | 0.24 |
| 2024-11-18 | 0.25 |
| 2024-11-15 | 0.24 |
| 2024-11-14 | 0.23 |
| 2024-11-13 | 0.23 |
| 2024-11-12 | 0.22 |
| 2024-11-11 | 0.22 |
| 2024-11-08 | 0.22 |
| 2024-11-07 | 0.21 |
| 2024-11-06 | 0.24 |
| 2024-11-05 | 0.25 |
| 2024-11-04 | 0.25 |
| 2024-11-01 | 0.24 |
| 2024-10-31 | 0.24 |
| 2024-10-30 | 0.25 |
| 2024-10-29 | 0.26 |
| 2024-10-28 | 0.26 |
| 2024-10-25 | 0.26 |